iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19

by Brad Kilner | May 7, 2020 | News | 0 comments

PRESS RELEASE

 

iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19

Burgess Hill, UK, 07 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has today announced that Professor Jeffrey Almond will be joining the board as they step up their efforts in search of a vaccine for COVID-19.

Professor Almond is an Oxford Martin Visiting Fellow with the Oxford Martin Programme on Vaccines and Former Vice President, Head of Discovery Research and External R&D at Sanofi Pasteur and Visiting Professor at the William School of Pathology, University of Oxford. He has been published extensively, especially in the field of virology.

Wayne Channon, Chairman of iosBio, commented: “I’m really excited by Professor Almond’s appointment. He brings with him a wealth of knowledge and expertise in developing successful vaccines and I am confident that his knowledge will strengthen our team.”

Speaking about his appointment, Professor Almond stated: “I am delighted to be joining the board and working with like-minded professionals using iosBio’s unique stabilisation technology. COVID-19 is a unique disease, and so at iosBio we have taken a unique approach. Ours is currently the only stabilised oral vaccine in development, meaning it targets both systemic and mucosal immunity, crucial for effective widespread immunisation against COVID-19.”

iosBio’s bid to find £6m to further develop their innovative oral capsule OraPro-COVID-19 means Almond’s appointment is timely. His previous work includes the completion of the genetic map of an avian influenza virus, the first detailed description of the proteins of Influenza B virus, and determination of the genetic basis of attenuation of the oral polio vaccine.

For more information on the science behind OraPro-COVID-19, or for interviews with Professor Jeffery Almond or, Wayne Channon, please email: iosBio@copestone.uk.com

End of press release (289 words)

Downloadable media assets

Press release doc Full Zip Download
iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19 iosBio_press_release_media_download iosBio Logo